News and Trends 6 Aug 2019 ADC Therapeutics and SOPHiA Genetics Team Up to Personalize Cancer Treatment Two companies based in Lausanne, Switzerland — ADC Therapeutics and the genomics company SOPHiA Genetics — have signed a deal to identify patients most likely to respond to a blood cancer drug. ADC Therapeutics will send SOPHiA Genetics blood samples collected from an ongoing phase II trial. The trial is testing a treatment for patients […] August 6, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 5 Aug 2019 Phase II Promise for Inhaled Chronic Lung Disease Treatment A first-in-class inhaled drug developed by the UK biotech Verona Pharma improved lung function in a phase II trial treating the lung condition chronic obstructive pulmonary disease. The 37 patients in the trial had chronic obstructive pulmonary disease (COPD), a common lung condition that involves a tightening of the lung airways and breathlessness. Verona Pharma […] August 5, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2019 Oncolytic Virus for Liver Cancer Ruled Futile in Phase III A phase III trial testing an oncolytic virus treatment for liver cancer, developed by the French biotech Transgene, has been discontinued after interim analyses concluded that the treatment was unlikely to succeed. Originally expected to finish in 2020, the phase III trial tested the oncolytic virus treatment Pexa-Vec in patients with the liver cancer hepatocellular […] August 2, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 2 Aug 2019 This Biotech Uses Messenger RNA to Treat Lethal Lung Inflammation Based close to Berlin, Germany, the biotech startup Pantherna Therapeutics is developing a messenger RNA drug to treat a life-threatening lung condition that requires mechanical ventilation. Mission: To develop a messenger RNA (mRNA) drug to treat acute respiratory distress syndrome, an inflammatory lung reaction that kills up to half of patients with the condition. Acute […] August 2, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 1 Aug 2019 Atlantic Healthcare’s Inflammatory Bowel Disease RNA Drug Fails Phase III Hopes of seeing an approved treatment for the inflammatory bowel condition pouchitis have been dashed as the UK company Atlantic Healthcare’s RNA drug has proved ineffective in a phase III trial. The trial tested Atlantic Healthcare’s RNA drug alicaforsen as a treatment for patients with pouchitis. Patients with this condition have their colon surgically replaced […] August 1, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Expert Advice 1 Aug 2019 How to Use Case Studies to Take Your Life Science Marketing Strategy to the Next Level To build a great relationship with a business partner, laying a foundation of trust is essential. But how can a potential partner trust you if they have no concept of how you work? Case studies can help communicate trust and show your potential partner how they can improve their life science marketing strategy by working […] August 1, 2019 - 6 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jul 2019 British Biotech Raises €11M to Market Personalized Medicine Test The UK biotech PredictImmune has raised €11M (£10M) in a Series B fundraising round to commercialize technology to predict the progress of inflammatory bowel disease in newly diagnosed patients. The funds will finance the global launch of PredictSURE IBD, a blood test that can identify patients with the most severe cases of inflammatory bowel disease, […] July 31, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jul 2019 Wellington Partners Raises €210M to Invest in European Life Sciences VC firm Wellington Partners has raised its fifth fund dedicated to investing in life science companies, with a major focus on those located in German-speaking countries. Wellington Partners has well surpassed its initial target of €150M for its fifth life sciences fund. With a total €210M raised, this new fund is more than double the […] July 31, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jul 2019 French Biotech’s Insulin Resistance Treatment Boosted by €67M Series A The French company Alizé Pharma III has raised a Series A round of €67M to push two peptide drugs into phase I, including a drug treating rare genetic conditions causing insulin resistance. The money will advance Alizé Pharma III’s two preclinical drugs into clinical trials, with phase I trials expected to begin in 2020. One […] July 31, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 30 Jul 2019 The First Approved NASH Therapy? Genfit is poised to become the first company to get a treatment for NASH to market — something that could happen as early as 2020, should its late 2019 phase III trial results be positive. I spoke to Dean Hum, the current COO and CSO of Genfit, to find out more about the company’s 20-year […] July 30, 2019 - 6 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jul 2019 Belgian Biotech Raises €35M to Develop Eco-Friendly Pesticides The Belgium-based company AgroSavfe has raised a Series C round of €35M to develop an environmentally friendly crop pesticide inspired by llama antibodies. AgroSavfe will use the funds to develop and manufacture its lead protein fungicide on a commercial scale. The company aims to get approval from the US Environmental Protection Agency and launch the […] July 30, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Expert Advice 30 Jul 2019 How to Build a Winning Life Science Content Marketing Strategy The data are in. Content works. As the internet matured, buyers in all industries began educating themselves before making a buying decision. When prospects get in touch with you, they’ve likely made up their mind already. How, then, can you affect their decision? “Publish or perish” has been standard advice for scientists since the early […] July 30, 2019 - 12 minutesmins - By James Mathison Share WhatsApp Twitter Linkedin Email